Medicare acts to cut some wholesale drug prices by up to one-third

Why This Topic Matters

The piece describes a Medicare reimbursement adjustment that could materially affect how office-based drug claims are paid and how practices manage acquisition costs, inventory, and access to treatment. It also places the change in the context of agency policy, congressional interest, and professional society reaction.

Article Sections

1. Medicare drug reimbursement policy change

   Overview of the HCFA policy update affecting office-administered drugs and the general purpose of the reimbursement change.

2. Industry and clinical response

   Statements from professional groups and practice representatives about the broader operational and financial effects of the update.

3. HCFA and congressional context

   Background on agency communications, congressional oversight, and prior reform efforts discussed in connection with the policy.

4. Sample of drugs slated for cuts

   A listing of selected drugs and dosage measurements identified in the draft materials referenced by the article.

5. Drugs not covered by Medicare

   Brief note identifying drugs that were excluded from Medicare coverage in the source material.